Due to the trading volumes seen in shares in Emotra and the large share price rise in its wake, the Company feels compelled to comment the situation. 200212 - Emotra - PM - Emotra comments on share trade volumes and the share price rise
The Company is now taking an important first step for the new indication area for EDOR® Test – depression relapse. 200206 - Emotra - PM - Emotra signs agreement for research collaboration
At the end of 2019, Emotra AB (“Emotra”) were interviewed by the management team at AstraZeneca BioVentureHub, after which we were offered space at the pharmaceutical company’s research facility in Mölndal, Sweden. 200130- Emotra - Newsletter - New office and...
Lately, Lars-Håkan Thorell from Emotra AB (“Emotra”) has been presenting the fundamental biological mechanisms behind hyporeactivity at various scientific symposiums. 191127 - Emotra -PM - Lectures
The Board of Directors and the CEO of Emotra AB hereby present the interim report for the first nine months of 2019. 191024 Interim report Jan-Sept 2019
Emotra AB (“Emotra”) is presently negotiating about research collaborations on EDOR® Test with prominent university hospitals in several European countries. 190925 - Emotra -Newsletter - Research collaborations
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first six months of 2019. 190823 Interim report Jan-June 2019
Emotra AB (“Emotra”) has had an eventful spring. New data which show that EDOR® can identify patients with an increased risk of depressive relapse are turning out to be more and more important. Emotra is now increasingly engaged in discussions with psychiatric...
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first quarter 2019. 190515 Interim report Jan-March 2019
The Annual General Meeting of EMOTRA AB (publ) was held today, May 15, 2019. The resolutions, summarised below, were all adopted with the necessary majority. 190515 - Emotra- PM - Communiqué from AGM
